TR199900056T2 - Leptin direncinin yeni tedavisi. - Google Patents

Leptin direncinin yeni tedavisi.

Info

Publication number
TR199900056T2
TR199900056T2 TR1999/00056T TR9900056T TR199900056T2 TR 199900056 T2 TR199900056 T2 TR 199900056T2 TR 1999/00056 T TR1999/00056 T TR 1999/00056T TR 9900056 T TR9900056 T TR 9900056T TR 199900056 T2 TR199900056 T2 TR 199900056T2
Authority
TR
Turkey
Prior art keywords
leptin resistance
new treatment
leptin
treatment
resistance
Prior art date
Application number
TR1999/00056T
Other languages
English (en)
Turkish (tr)
Inventor
Henry Poste George
Alistair Smith Stephen
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614740.0A external-priority patent/GB9614740D0/en
Priority claimed from GBGB9614751.7A external-priority patent/GB9614751D0/en
Priority claimed from GBGB9616412.4A external-priority patent/GB9616412D0/en
Priority claimed from GBGB9616409.0A external-priority patent/GB9616409D0/en
Priority claimed from GBGB9616407.4A external-priority patent/GB9616407D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of TR199900056T2 publication Critical patent/TR199900056T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Peptides Or Proteins (AREA)
TR1999/00056T 1996-07-12 1997-07-14 Leptin direncinin yeni tedavisi. TR199900056T2 (xx)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9614740.0A GB9614740D0 (en) 1996-07-12 1996-07-12 Novel treatment
GBGB9614751.7A GB9614751D0 (en) 1996-07-12 1996-07-12 Novel treatment
GBGB9616412.4A GB9616412D0 (en) 1996-08-05 1996-08-05 Novel treatment
GBGB9616409.0A GB9616409D0 (en) 1996-08-05 1996-08-05 Novel treatment
GBGB9616407.4A GB9616407D0 (en) 1996-08-05 1996-08-05 Novel treatment

Publications (1)

Publication Number Publication Date
TR199900056T2 true TR199900056T2 (xx) 1999-04-21

Family

ID=27517363

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00056T TR199900056T2 (xx) 1996-07-12 1997-07-14 Leptin direncinin yeni tedavisi.

Country Status (12)

Country Link
EP (1) EP0921798A1 (xx)
JP (1) JP2000514807A (xx)
KR (1) KR20000023719A (xx)
CN (1) CN1230114A (xx)
AU (1) AU3552697A (xx)
BR (1) BR9710272A (xx)
CA (1) CA2260044A1 (xx)
NO (1) NO990097D0 (xx)
PL (1) PL331148A1 (xx)
TR (1) TR199900056T2 (xx)
TW (1) TW442288B (xx)
WO (1) WO1998002159A1 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
WO1999044598A2 (en) * 1998-03-03 1999-09-10 Board Of Regents, The University Of Texas System Methods for inhibiting βcell apoptosis
MXPA01010916A (es) * 1999-04-28 2002-06-21 Reddy Research Foundation Heterociclos biciclicos sustituidos, procedimiento para su preparacion y su uso como agentes contra la obesidad y como agentes hipocolesterolemicos.
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
EP2065044A1 (en) 2001-04-04 2009-06-03 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
ES2609395T5 (es) 2004-03-12 2021-08-06 Intercept Pharmaceuticals Inc Tratamiento de la fibrosis usando ligandos de Fxr
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
EP2324046B1 (en) 2008-07-30 2014-09-03 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
SI2698375T1 (sl) 2008-11-19 2018-10-30 Intercept Pharmaceuticals, Inc. Modulatorji TGR5 in njihova uporaba
JP2015521621A (ja) 2012-06-19 2015-07-30 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸の調製、使用および固体形態
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
DK0601001T3 (da) * 1991-08-26 1997-10-20 Upjohn Co Flydende næringsmiddelprodukt indeholdende 3-guanidinopropionsyre.
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
JP2000514807A (ja) 2000-11-07
NO990097L (no) 1999-01-11
AU3552697A (en) 1998-02-09
CN1230114A (zh) 1999-09-29
NO990097D0 (no) 1999-01-11
TW442288B (en) 2001-06-23
BR9710272A (pt) 1999-08-10
PL331148A1 (en) 1999-06-21
EP0921798A1 (en) 1999-06-16
CA2260044A1 (en) 1998-01-22
WO1998002159A1 (en) 1998-01-22
KR20000023719A (ko) 2000-04-25

Similar Documents

Publication Publication Date Title
TR199900056T2 (xx) Leptin direncinin yeni tedavisi.
ATE234323T1 (de) N6-heterocyclisch substituierte adenosin-derivate
ZA961150B (en) Substituted isoxazoles for the treatment of inflammation.
DE69730043D1 (de) Implantierbare eletrodenleitung
BR9605486A (pt) Pneumático tendo uma armadura de carcaça radial
DE69732105D1 (de) Programmerweiterbare, implantierbare, medizinische vorrichtung
IS4963A (is) Setnar 6,5-heteró-bísýklískar afleiður
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
DE69631044D1 (de) N,o-carboxymethylchitosan zur verhinderung operativ bedingter adhäsionen
GR3034564T3 (en) Lactone derivatives of 17.beta.-carboxy, carbothio and amide androstane derivatives
HUT74714A (en) 1,2,4-oxadiazole derivatives and their use as parasiticides for animals
RS49723B (sr) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
EP0641209A4 (en) NEW 17-ESTER, AMID AND KETONE DERIVATIVES OF 3-OXO-4-AZASTEROIDS AS 5-ALPHA REDUCTINE INHIBITORS.
ZA973707B (en) Method for treating inflammation.
EP1135144A4 (en) COMPOSITIONS AND METHODS OF REGULATING BACTERIAL PATHOGENESIS
EP0679603A3 (en) Method for adjusting an elevator door.
AU6198299A (en) Device and method for sterilising screwcaps
AU2001289123A1 (en) Compounds and methods for diagnosing and treating amyloid-related conditions
GB9601779D0 (en) 9, 10 Disubstituted camptothecin derivatives
TW336890B (en) Method of making more than one punchout from a single dried blood spot
EP1083914A4 (en) TREATING ARTHRITIS AND OTHER SIMILAR DISORDERS
IT1292829B1 (it) Metodo e dispositivo per il controllo di banconote.
DE59508403D1 (de) 14alpha,17alpha-c2-überbrückte 19-nor-progesteronderivate
AU4882897A (en) Disinfectant composition, particularly for the prevention of dermatitis induced by diapers, and method for its use
BR9510036A (pt) Derivados de 1,3,4-oxadiazina